Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 21.69
(-2.58%)
USD 21.69
(-2.58%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -153.89 Million | -136.13 Million | 171.22 Million | -95.39 Million | 173.03 Million | -47.22 Million |
| Net Income | -209.27 Million | -176.49 Million | -140.84 Million | -84.55 Million | 67.97 Million | -54.45 Million |
| Depreciation & Amortization | 12.49 Million | 10.42 Million | 8.26 Million | 5.94 Million | 4.43 Million | 4.69 Million |
| Deferred income taxes | -34.4 Million | - | - | - | - | -432.14 Thousand |
| Stock-based compensation | 78.13 Million | 120.89 Million | 76.67 Million | 43.38 Million | 12.39 Million | 8.45 Million |
| Change in working capital | -51.54 Million | -98.29 Million | 226.86 Million | -60.68 Million | 87.15 Million | -5.87 Million |
| Other non-cash items | 50.71 Million | 7.34 Million | 266 Thousand | 525.3 Thousand | 1.06 Million | 383.07 Thousand |
| Investing Cash Flow | -96.15 Million | -5.41 Million | -141.67 Million | -240.77 Million | -47.74 Million | -7.43 Million |
| Investments in PPE | -176.73 Million | -52.77 Million | -23.56 Million | -11.95 Million | -12 Million | -1.42 Million |
| Acquisitions | -80.58 Million | -47.36 Million | 141.67 Million | 240.77 Billion | 47.74 Billion | 7.43 Billion |
| Investment purchases | -246.14 Million | -223.39 Million | -240.7 Million | -278.96 Million | -90.26 Million | -52.08 Million |
| Sales/Maturities of investments | 326.72 Million | 270.75 Million | 122.59 Million | 50.13 Million | 54.52 Million | 46.06 Million |
| Other Investing Activities | 80.58 Million | 47.36 Million | -141.67 Million | -240.77 Billion | -47.74 Billion | -7.43 Billion |
| Financing Cash Flow | 253.05 Million | 65.18 Million | 11.3 Million | 257.94 Million | 66.38 Million | 59.95 Million |
| Debt repayment | -250 Million | - | - | - | -2.41 Million | -208.5 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | -54.66 Thousand |
| Common Stock Issuance | 3.05 Million | 5.18 Million | 11.3 Million | 250.47 Million | 60.52 Million | 60.16 Million |
| Other Financing Activities | 253.05 Million | 60 Million | 11.3 Million | 7.46 Million | 8.27 Million | 60.21 Million |
| Accounts receivables | 1.41 Million | 8.84 Million | -9.4 Million | -184.31 Thousand | -333.98 Thousand | -259.57 Thousand |
| Accounts payables | 32.99 Million | -6.58 Million | 2.62 Million | -821.01 Thousand | 4.84 Million | -1.27 Million |
| Inventory | -3.36 Million | - | 9.16 Million | 1.6 Million | -1.26 Million | 1.33 Million |
| Other working capital | -82.59 Million | -100.54 Million | 224.48 Million | -61.28 Million | 83.9 Million | -5.68 Million |
| Cash at beginning of period | 108 Million | 184.43 Million | 143.58 Million | 221.8 Million | 30.13 Million | 24.83 Million |
| Cash at end of period | 110.89 Million | 108 Million | 184.43 Million | 143.58 Million | 221.8 Million | 30.13 Million |
| Capital Expenditure | -176.73 Million | -52.77 Million | -23.56 Million | -11.95 Million | -12 Million | -1.42 Million |
| Effect of forex changes on cash | -122 Thousand | -67 Thousand | -88 Thousand | 410 Thousand | - | - |
| Net cash flow / Change in cash | 2.88 Million | -76.42 Million | 40.85 Million | -78.22 Million | 191.67 Million | 5.29 Million |
| Free Cash Flow | -330.62 Million | -188.9 Million | 147.65 Million | -107.34 Million | 161.03 Million | -48.64 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -170.79 Million | -125.3 Million | -135.37 Million | -209.27 Million | -111.01 Million | -104.12 Million |
| Depreciation & Amortization | 4.78 Million | 4.52 Million | 4.26 Million | 12.49 Million | 3.85 Million | 3.27 Million |
| Deferred income taxes | - | - | -915 Thousand | -34.4 Million | -2.01 Million | - |
| Stock-based compensation | 17.05 Million | 17.75 Million | 19.69 Million | 78.13 Million | 18.18 Million | 19.94 Million |
| Change in working capital | 24.64 Million | 3.36 Million | -10.87 Million | -51.54 Million | 59.44 Million | 55.24 Million |
| Other non-cash items | 24.32 Million | 30.01 Million | 5.36 Million | 50.71 Million | 6.29 Million | 4.21 Million |
| Investing Cash Flow | 6.94 Million | -268.93 Million | 64.83 Million | -96.15 Million | 30.5 Million | -9.9 Million |
| Investments in PPE | -14.44 Million | -34.07 Million | -68.65 Million | -176.73 Million | -63.9 Million | -46.6 Million |
| Acquisitions | - | - | - | -80.58 Million | -94.41 Million | -36.7 Million |
| Investment purchases | -118.62 Million | -309.98 Million | - | -246.14 Million | -12.15 Million | -41.45 Million |
| Sales/Maturities of investments | 140.02 Million | 75.12 Million | 133.49 Million | 326.72 Million | 106.57 Million | 78.15 Million |
| Other Investing Activities | 21.39 Million | -234.86 Million | 133.49 Million | 80.58 Million | 94.41 Million | 36.7 Million |
| Financing Cash Flow | 50.38 Million | 430.77 Million | 267 Thousand | 253.05 Million | 152 Thousand | 1.8 Million |
| Debt repayment | -50 Million | - | - | -250 Million | -250 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 387 Thousand | 430.77 Million | 267 Thousand | 3.05 Million | 821 Thousand | 1.13 Million |
| Other Financing Activities | 50.38 Million | 430.77 Million | 267 Thousand | 253.05 Million | 152 Thousand | 1.8 Million |
| Accounts receivables | - | - | - | 1.41 Million | 1.24 Million | 68.18 Million |
| Accounts payables | 11.18 Million | 4.06 Million | -12.46 Million | 32.99 Million | 27.99 Million | -1.68 Million |
| Inventory | - | - | - | -3.36 Million | 807 Thousand | 1.59 Million |
| Other working capital | 13.45 Million | -693 Thousand | 1.59 Million | -82.59 Million | 29.39 Million | -12.85 Million |
| Cash at beginning of period | 127.7 Million | 58.21 Million | 110.89 Million | 108 Million | 105.33 Million | 134.95 Million |
| Cash at end of period | 69.39 Million | 127.7 Million | 58.21 Million | 110.89 Million | 110.89 Million | 105.33 Million |
| Capital Expenditure | -14.44 Million | -34.07 Million | -68.65 Million | -176.73 Million | -63.9 Million | -46.6 Million |
| Effect of forex changes on cash | -223 Thousand | 26 Thousand | 58 Thousand | -122 Thousand | 153 Thousand | -79 Thousand |
| Net cash flow / Change in cash | -58.3 Million | 69.48 Million | -52.67 Million | 2.88 Million | 5.55 Million | -29.62 Million |
| Free Cash Flow | -129.86 Million | -126.45 Million | -186.49 Million | -330.62 Million | -89.16 Million | -68.05 Million |
FF
601615
VGPBF
NWBO
002942
MYCR